Impact of adverse events-associated dose modifications of PARP inhibitors on treatment outcomes in primary ovarian cancer
Artículo
Acceso abierto
Artículo
DOAJ
Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPis) are the standard of care for primary ovarian cancer (OC), yet adverse events (AEs) frequently necessitate dose modifications. The prognostic impact of ...
LCC TENDOkd5bmVjb2xvZ3kgYW5kIG9ic3RldHJpY3M~Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access